We had 479 females (95.2%) and 24 males (4.8%). The age extremes were 16 years and 78 years, with a mean age of 48.4 ± 10.4 years. Age was <40 years in 63 (12.5%). The predominant age range was 45 - 54 (46.3%) and the majority of patients were married (52.5%). Most patients had a secondary level of education (48.9%), and were unemployed (43.7%). Natives of the Centre (43.5%) and West (38.0%) regions were the most represented (Table 1).

Table 1. Distribution of cases of breast cancer according to sociodemographic characteristics at two referral hospitals of Yaoundé from 2015 to 2019 (N = 503).

*Others: South 14, North-west 14, South-west 11, East 11, Littoral 9, Foreigners 9, unspecified 6.

Of the 479 women, 7.3% were nulligravidas, 7.5% primigravidas, 30.1% paucigravidas (2 - 3 pregnancies), 37.4% multigravidas (4 - 5 pregnancies), and 17.7% grand multigravidas. With respect to parity, 7.7% were nulliparous, 12.1% primiparous, 42.4% pauciparous (2 - 3 deliveries), 31.5% multiparous, and 6.3% grand multiparous.

3.2.1. Clinical Characteristics and Staging of BC in the Study Population

The median time from onset of symptoms to consultation was 2.9 [1.9 - 5.9] months, with extremes of 3 days and 4 years. Majority of patients (53.1%) consulted within 3 months following the onset of symptoms with breast nodules being the main complaint in 86.9% of cases. The majority of breast cancer cases were diagnosed at Stage III (36.6%) or IV (38.2%), as shown in Table 2.

Table 2. Distribution of population according to time lapse and reason for consultation.

3.2.2. Histopathological Characteristics and Grading of BC in the Study Population

Invasive ductal carcinoma was the most common histological type of BC, accounting for 80.9%. Grade II was the most predominant tumour grade with 71.8% (Table 3).

Complete immunohistochemistry was performed by 7.8% (39/503) of patients. However, up to 63 did hormone receptor testing. BC was mostly progesterone receptor negative (90.5%) and HER 2 negative (89.8%) and the most represented subtype was triple negative BC (64.1%), followed by luminal A (25.6%). All tested for ki67 were negative (Table 4).

Table 3. Distribution of breast cancer cases according to histological types, tumour grade, and TNM stage at two referral hospitals of Yaoundé from 2015 through 2019 (N = 503).

Table 4. Prevalence of biological (immunohistochemistry) receptors among breast cancers at two referral hospitals of Yaoundé from 2015 to 2019.

The most common therapeutic regimens recorded were chemotherapy alone (46.5%) and surgery + chemotherapy (44.7%) as presented in Table 5.

Table 5. Distribution of breast cancer cases at two referral hospitals of Yaoundé from 2015-2019 according to treatment modalities.

The Kaplan-Meier curve showed that the median survival of the population was 67.2 months (95% CI: 63.7 - 70.7). The 5-year (60 months) survival rate was 51.9% (Figure 1).

Figure 1. Kaplan-Meier survival curve of breast cancer cases managed at two hospitals in Yaoundé from 2015 to 2019.

Multivariate Cox proportional hazards regression identified several independent predictors of overall survival. Male sex (aHR: 7.07; 95% CI: 3.97 - 12.57; p < 0.001), consultation delay ≥ 6 months (aHR: 2.20; 95% CI: 1.66 - 2.90; p < 0.001), invasive ductal carcinoma (aHR: 2.01; 95% CI: 1.30 - 3.10; p = 0.002), and advanced stage (aHR: 4.92; 95% CI: 3.14 - 7.71; p < 0.001) were most prominently associated with poorer survival. University level of education (aHR: 0.57; 95% CI: 0.40 - 0.83; p = 0.003) and combined treatment including surgery (aHR: 0.73; 95% CI: 0.56 - 0.95; p = 0.021) were associated with improved survival (Table 6).

Table 6. Independent predictors of overall survival among breast cancer patients treated at two referral hospitals of Yaoundé (2015-2019).

TNM: tumour, nodes and metastases, aHR: adjusted hazard ratio.

A possible limitation to our study is the fact that many files were not found or excluded because records were not optimally organized and some files were poorly filled. This could have introduced some form of selection bias, leading to a misrepresentation of breast cancer characteristics and outcome in our setting. This was further compounded by the retrospective nature of our data collection. However, we could not afford the length of time required for a prospective approach, and so opted to be exhaustive, including all the cases we could, and working at two hospitals that concentrate BC cases.

The mean age of the study population was 48.4 ± 10.4 years and the extremes 16 - 78 years. This result is consistent with a study carried out in Benin in 2024, which reported a mean age of 48.74 ± 11.73 years and extreme ages of 19 to 85 years [7]. Patients in our study reflect a trend consistent with previous research, highlighting the burden of breast cancer among relatively younger women. This finding underscores the potential influence of genetic, lifestyle and environmental factors unique to our demographics. Our study population was predominantly female (95.2%), a finding that aligns with global figures that show BC mainly affects women.

Most participants were married (52.5%), had a secondary education level (48.9%), were unemployed (43.7%), lived in an urban area (63.4%), and hailed from the Centre (43.5%) or West (38.0%) region. This is similar to findings by other Cameroon studies [4][8]. These figures reflect the demographics of women in Cameroonian cities in line with the Demographic and Health Survey of 2018 [9]. They also highlight the socioeconomic challenges faced by our study participants.

Most participants had had more than two pregnancies (84.9%), exceeding the values recorded in Cameroon in 2024 (57.4%) [4]. Possible reasons for higher results in our studies could be accounted for by differences in cultural and societal norms around family planning, reproductive health, and childbearing in our study population.

Of the 503 BC cases we included, 267 (53.1%) sought consultation within 3 months of symptom onset, with a range of 3 days to 4 years. These findings are similar to studies in Benin, where most participants (78.4%) consulted within 6 months [7].

The primary reason for consultation was an incidental discovery of a breast nodule by patients in 86.9% of cases. This result correlates with studies in Cameroon, where most patients (54.29%) presented with a breast nodule [10]. Breast cancer was unilateral in 94.8% of cases, predominantly left-sided in 69.6% of cases, with the upper-outer quadrant most commonly affected (64.4%). These findings align with a 2015 Cameroonian study, where left breast cancer was more frequent (52%), and the upper-outer quadrant was most commonly affected [11]. However, our result differs from a Nigerian study in 2010, where 52.2% of breast tumours were in the right breast [12]. This discrepancy may be due to differences in biological or environmental factors.

At clinical diagnosis, a breast nodule was found in 91.1% of cases, often associated with other symptoms. Most BC cases were diagnosed at Stage III (36.6%) or IV (38.2%), consistent with a 2022 study in Cameroon, where 21.1% and 48.2% of patients were diagnosed with clinical stages 3 and 4, respectively [2]. The late-stage diagnosis in our study, is a common trend in developing countries, which could be explained by the limited access to screening and late consultation.

Invasive ductal carcinoma was the most common histological type of BC, accounting for 80.9% of cases. This finding is consistent with studies conducted in Cameroon, where 96.9% to 84.7% of participants had this histological type [4][10]. Similarly, a study in Southwest Nigeria in 2021 found that invasive ductal carcinoma was the most prevalent (89.2%), followed by invasive lobular carcinoma (6.6%) [13].

The majority of tumours were Grade II (71.8%), followed by Grade III (19.5%), and then Grade I (8.7%). This indicates that the majority of tumours were moderately aggressive and required combined therapeutic modalities. These findings align with other Cameroonian studies, where most participants were diagnosed with Grade II breast cancers [2][8]. Additionally, 2015 studies in Cameroon found that SBR II was the most frequent grade (66%), followed by SBR III (20%), and grade I (14%) [11].

BC tumours were predominantly progesterone receptor-negative (90.5%), followed by HER2-negative breast cancer (89.8%). Immunohistochemistry was performed in 7.8% of patients, revealing that the most represented subtype was triple-negative breast cancer (64.1%), followed by luminal A (25.6%). This result is consistent with earlier studies in Cameroon (2024), which revealed a high proportion of poor prognostic features with triple-negative and luminal A tumours most represented [4].

The most common therapeutic regimens for BC treatment were chemotherapy alone (46.5%) and a combination of surgery and chemotherapy (44.7%), accounting for over 90% of cases. This finding is consistent with a study in Cameroon, which reported that chemotherapy was the most common type of conventional therapy employed [8].

The high proportion of patients receiving chemotherapy alone or surgery + chemotherapy is supported by the observation that many patients presented with advanced disease (Stage III and IV) requiring systemic treatment for locally advanced disease and metastases.

Radiotherapy was used in only a small proportion of cases (2%), often in combination with other treatment modalities. A possible explanation for this low utilization is the absence of a radiotherapy unit in Yaoundé, such that patients are referred to Douala for radiotherapy. This increases the risk of patients being lost to follow-up.

The Kaplan-Meier survival curve indicates that the median survival time for the study population was 67.2 months (95% CI: 63.7 - 70.7 months). At 5 years (60 months), the survival rate was 51.9%, meaning that approximately half of the study population survived for 5 years following diagnosis.

This finding is consistent with the trend of low 5-year survival rates reported in Sub-Saharan Africa. For instance, in Southwest Nigeria reported 5-year survival rates was 37.6%, for patients diagnosed and treated between 2004 and 2008 [13]. The difference in survival rates may be attributed to the fact that this study focused on patients with a more recent follow-up (2015-2019), suggesting advances in therapeutic modalities which could have contributed to improved survival rates in this study.

However, 5-year survival rates in Africa remain significantly lower compared to developed countries [14]. Several factors may contribute to the low survival rates in Africa such as late-stage diagnosis, financial constraints limiting access to adequate treatment, superstitious beliefs surrounding BC, and the quest for healing through prayers alone.

After multivariate analysis, the independent factors associated with a decrease survival included being a male (7-times risk). This is in line with studies carried out in 2024 which stated that men had higher death rates than women across all stages of BC [15]. This may also be due to lack of awareness among men, leading to late-stage diagnosis. The observation that patients residing in rural areas were less likely to survive BC (aHR 1.71; p < 0.001) is in line with an international review and meta-analysis in 2018, which stated that rural-dwellers were more likely to die when they developed BC than urban-dwellers (HR: 1.05, 95%CI 1.02 - 1.07) [16]. However, our figure was bigger probably in relation to beliefs mentioned above, as well as challenges in accessing specialized care.

Presenting more than 6 months after the onset of symptoms was associated with poorer survival (HR: 2.20; p < 0.001), as was a TNM stage of 3 or 4 (HR: 4.92; p < 0.001). had a significantly higher risk of decreased survival in breast cancer. These results were similar to those observed in Cameroon in 2022 where clinical stage 3 (p = 0.010) was associated with a reduction in survival [4]. Spread to nearby tissues and lymph nodes, and distant metastasis make it more challenging to achieve complete remission, even with adequate resources.

Patients diagnosed with invasive ductal carcinoma, or Grade 3 disease had decreased survival rates than patients diagnosed with other histological types (HR: 2.01). This is attributed to the greater aggressiveness associated with these histological features [17]. Aggressive tumours spread more quickly to attain stages III and IV, which are associated with poorer survival.